Evidence map›Paper›PMID 42293295›Full record

ArticleBiofilm2026

Evidence of cefiderocol-persistence in

Gianmarco Mangiaterra, Massimiliano Lucidi, Giorgia Piccioni, Riccardo Rosa, Davide Gugliandolo, Ida De Fino, Martina Rossano, Carla Vignaroli, Paolo Visca, Alessandra Bragonzi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biofilm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gianmarco MangiaterraDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Biotechnology Section, Fano, 61032, Italy.
Massimiliano LucidiDepartment of Science, University Roma Tre, Rome, 00154, Italy.
Giorgia PiccioniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Biotechnology Section, Fano, 61032, Italy.
Riccardo RosaDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Biotechnology Section, Fano, 61032, Italy.
Davide GugliandoloInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy.
Ida De FinoInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy.
Martina RossanoInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy.
Carla VignaroliDepartment of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, 60131, Italy.
Paolo ViscaDepartment of Science, University Roma Tre, Rome, 00154, Italy.
Alessandra BragonziInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy.
Barbara CitterioDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Biotechnology Section, Fano, 61032, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Persistent and viable but non-culturable (VBNC) Methods: Results: A higher amount of culturable Conclusions: Overall, these findings emphasize the capacity of

Indexed as

Antibiotic persistenceChronic infectionsCystic fibrosisPseudomonas aeruginosaVBNC cells

Identifiers

PMID42293295
PMCPMC13253140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.